Epitalon vs MOTS-c
How they differ
- FDA status, the same for both (Not FDA-approved). Epitalon: Not an FDA-approved drug.1 MOTS-c: Not an FDA-approved drug.2
- Kinds of studies cited. Epitalon: limited human data. MOTS-c: animal and lab studies only. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Epitalon | MOTS-c |
|---|---|---|
| What it is | A synthetic peptide of four amino acids (Ala-Glu-Asp-Gly). FDA treats it as a different substance from epithalamin, a pineal-gland extract it was modeled on.1 | A naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA. FDA’s evaluation covers synthetic free-base and acetate forms.2 |
| FDA status | Not FDA-approved Not an FDA-approved drug1 Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,4 | Not FDA-approved Not an FDA-approved drug2 Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,3,4 |
| HHS compounding policy, October 30, 2026 | In the policy: one of the six peptides it lists.4 | In the policy: one of the six peptides it lists.4 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists epitalon among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.5 | The profile does not say whether the current page lists it. HHS’s policy document states that MOTS-c was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.4,5 |
| Kinds of studies cited |
|
|
| Records collected | 0 ClinicalTrials.gov records and 24 PubMed records collected | 0 ClinicalTrials.gov records and 41 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA briefing document for epitalon ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026